References of "Seeman, E"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older
Seeman, E.; Vellas, B.; Benhamou, C. L. et al

in Journal of Bone and Mineral Research (2006), 21(7), 1113-1120

Introduction: About 25-30% of the population burden of all fragility fractures in the community arise from women >= 80 years of age, because this population is at high risk for all types of fracture ... [more ▼]

Introduction: About 25-30% of the population burden of all fragility fractures in the community arise from women >= 80 years of age, because this population is at high risk for all types of fracture, particularly nonvertebral fractures. Despite this, evidence that therapies reduce the risk of both vertebral and nonvertebral fractures in this group is lacking. The aim of this study was to determine whether strontium ranelate, an agent that reduces the risk of vertebral and nonvertebral fractures in postmenopausal women > 50 years of age, also reduces fractures in the elderly. Materials and Methods: An analysis based on preplanned pooling of data from two international, phase 111, randomized, placebo-controlled, double-blind studies (the Spinal Osteoporosis, Therapeutic Intervention [SOTI] and TReatment Of Peripheral OSteoporosis [TROPOS]) included 1488 women between 80 and 100 years of age followed for 3 years. Yearly spinal X-rays were performed in 895 patients. Only radiographically confirmed nonvertebral fractures were included. Results: Baseline characteristics did not differ in placebo and treatment arms. In the intent-to-treat analysis, the risk of vertebral, nonvertebral, and clinical (symptomatic vertebral and nonvertebral) fractures was reduced within I year by 59% (p = 0.002), 41% (p = 0.027), and 37% (p = 0.012), respectively. At the end of 3 years, vertebral, nonvertebral, and clinical fracture risks were reduced by 32% (p = 0.013), 31% (p = 0.011), and 22% (p = 0.040), respectively. The medication was well tolerated, and the safety profile was similar to that in younger patients. Conclusions: Treatment with strontium ranelate safely reduces the risk of vertebral and nonvertebral fractures in women with osteoporosis >= 80 years of age. Even in the oldest old, it is not too late to reduce fracture risk. [less ▲]

Detailed reference viewed: 29 (3 ULiège)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral fracture in patients with osteopenia
Seeman, E.; Sawicki, A.; Reginster, Jean-Yves ULiege et al

in Osteoporosis International (2006, June), 17(Suppl.2), 85

Detailed reference viewed: 6 (1 ULiège)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of fracture in elderly women with osteoporosis in the first year of treatment
Seeman, E.; Vellas, B.; Benhamou, C. L. et al

in Osteoporosis International (2006, June), 17(Suppl.2), 85-86

Detailed reference viewed: 11 (2 ULiège)
See detailStrontium ranelate reduces the risk of vertebral fracture in patients with osteopenia
Seeman, E.; Sawicki, A.; Reginster, Jean-Yves ULiege et al

in Osteoporosis International (2006, May), 17(Suppl. 2), 209

Detailed reference viewed: 11 (4 ULiège)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral fracture in patients with osteopenia
Seeman, E.; Sawicki, A.; Reginster, Jean-Yves ULiege et al

in Osteoporosis International (2006, March), 17(Suppl.1), 50

Detailed reference viewed: 12 (0 ULiège)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of fracture in elderly women with osteoporosis in the first year of treatment
Seeman, E.; Vellas, B.; Benhamou, C. L. et al

in Osteoporosis International (2006, March), 17(Suppl.1), 7

Detailed reference viewed: 9 (0 ULiège)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study
Reginster, Jean-Yves ULiege; Seeman, E.; De Vernejoul, M. C. et al

in Journal of Clinical Endocrinology and Metabolism (2005), 90(5), 2816-2822

Background: Strontium ranelate, a new oral drug shown to reduce vertebral fracture risk in postmenopausal women with osteoporosis, was studied in the Treatment of Peripheral Osteoporosis (TROPOS) study to ... [more ▼]

Background: Strontium ranelate, a new oral drug shown to reduce vertebral fracture risk in postmenopausal women with osteoporosis, was studied in the Treatment of Peripheral Osteoporosis (TROPOS) study to assess its efficacy and safety in preventing nonvertebral fractures also. Methods: Strontium ranelate (2 g/d) or placebo were randomly allocated to 5091 postmenopausal women with osteoporosis in a double-blind placebo-controlled 5-yr study with a main statistical analysis over 3 yr of treatment. Findings: In the entire sample, relative risk (RR) was reduced by 16% for all nonvertebral fractures (P = 0.04), and by 19% for major fragility fractures (hip, wrist, pelvis and sacrum, ribs and sternum, clavicle, humerus) (P = 0.031) in strontium ranelate-treated patients in comparison with the placebo group. Among women at high risk of hip fracture ( age ≥ 74 yr and femoral neck bone mineral density T score ≤-3, corresponding to -2.4 according to NHANES reference) (n = 1977), the RR reduction for hip fracture was 36% (P = 0.046). RR of vertebral fractures was reduced by 39% (P < 0.001) in the 3640 patients with spinal x-rays and by 45% in the subgroup without prevalent vertebral fracture. Strontium ranelate increased bone mineral density throughout the study, reaching at 3 yr (P < 0.001): +8.2% (femoral neck) and +9.8% (total hip). Incidence of adverse events (AEs) was similar in both groups. Conclusion: This study shows that strontium ranelate significantly reduces the risk of all nonvertebral and in a high-risk subgroup, hip fractures over a 3-yr period, and is well tolerated. It confirms that strontium ranelate reduces vertebral fractures. Strontium ranelate offers a safe and effective means of reducing the risk of fracture associated with osteoporosis. [less ▲]

Detailed reference viewed: 113 (3 ULiège)
Full Text
Peer Reviewed
See detailVertebral and non-vertebral anti-fracture efficacy of strontium ranelate in very elderly women with osteoporosis
Seeman, E.; Vellas, B.; Meunier, Pierre J et al

in Osteoporosis International (2005, March), 16(Suppl.3), 6

Detailed reference viewed: 10 (0 ULiège)
Full Text
Peer Reviewed
See detailNovel ibandronate regimens in postmenopausal osteoporosis: design of the dosing intravenous administration (DIVA) study
Sambrook, P.; Reginster, Jean-Yves ULiege; Recker, R. R. et al

in Osteoporosis International (2004, May), 15(Suppl.1), 118

Detailed reference viewed: 14 (0 ULiège)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral fractures in postmenopausal women with osteopenia
Sawicki, A; Reginster, Jean-Yves ULiege; Roux, C et al

in Osteoporosis International (2004), 15(S1), 119-120

Detailed reference viewed: 10 (4 ULiège)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral fractures in postmenopausal women with osteopenia
Sawicki, A.; Reginster, Jean-Yves ULiege; Roux, C. et al

in Calcified Tissue International (2004), 74(S1), 84

Detailed reference viewed: 11 (2 ULiège)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women without prevalent vertebral fracture
Reginster, Jean-Yves ULiege; Balogh, A.; Badurski, J. et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 7-8

Detailed reference viewed: 10 (0 ULiège)
Full Text
Peer Reviewed
See detailEarly effect of strontium ranelate on clinical vertebral fractures in women with postmenopausal osteoporosis
Meunier, P. J.; Marquis, P.; Lemmel, E. M. et al

in BONE (2003), 32(S7), 222

Detailed reference viewed: 18 (7 ULiège)
Full Text
Peer Reviewed
See detailAdditive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis
Johnell, O.; Scheele, W. H.; Lu, Y. L. et al

in Journal of Clinical Endocrinology and Metabolism (2002), 87(3), 985-992

Both raloxifene (RLX) and alendronate (ALN) can treat and prevent new vertebral fractures, increase bone mineral density (BMD), and decrease biochemical markers of bone turnover in postmenopausal women ... [more ▼]

Both raloxifene (RLX) and alendronate (ALN) can treat and prevent new vertebral fractures, increase bone mineral density (BMD), and decrease biochemical markers of bone turnover in postmenopausal women with osteoporosis. This phase 3, randomized, double-blind 1-yr study assessed the effects of combined RLX and ALN in 331 postmenopausal women with osteoporosis (femoral neck BMD T-score, less than -2). Women (aged less than or equal to75 yr; greater than or equal to2 yr since their last menstrual period) received placebo, RLX 60 mg/d, ALN 10 mg/d, or RLX 60 mg/d and ALN 10 mg/d combined. At baseline, 6 and 12 months, BMD was measured by dual x-ray absorptiometry. The bone turnover markers serum osteocalcin, bone-specific alkaline phosphatase, and urinary N- and C-telopeptide corrected for creatinine were measured. The effects of RLX and ALN were considered to be independent and additive if the interaction effect was not statistically significant (P > 0.10) in a two-way ANOVA model. All changes in BMD and bone markers at 12 months were different between placebo and each of the active treatment groups, and between the RLX and RLX+ALN groups (P < 0.05). On average, lumbar spine BMD increased by 2.1,4.3, and 5.3% from baseline with RLX, ALN, and RLX+ALN, respectively. The increase in femoral neck BMD in the RLX+ALN group (3.7%) was greater than the 2.7 and 1.7% increases in the ALN (P = 0.02) and RLX (P < 0.001) groups, respectively. The changes from baseline to 12 months in bone markers ranged from 7.1 to -16.0% with placebo, -23.8 to -46.5% with RLX, -42.3 to -74.2% with ALN, and -54.1 to -81.0% in the RLX+ALN group. RLX and ALN increased lumbar spine and femoral neck BMD, and decreased osteocalcin and C-telopeptide corrected for creatinine in an additive and independent manner, because the interaction effects were not significant. Although the ALN group had changes in BMD and bone markers that were approximately twice the magnitude as in the RLX group, it is not known how well these changes correlate to the clinical outcome of fracture. RLX+ALN reduced bone turnover more than either drug alone, resulting in greater BMD increment, but whether this difference reflects better fracture risk reduction was not assessed in this study. [less ▲]

Detailed reference viewed: 78 (3 ULiège)
Full Text
Peer Reviewed
See detailEfficacy of risedronate in decreasing the incidence of femoral neck and intertrochanteric fractures in older women with osteoporosis
Eastell, R; McClung, MR; Reginster, Jean-Yves ULiege et al

in Journal of Bone and Mineral Research (2001), 16(S1), 219

Detailed reference viewed: 14 (1 ULiège)
Full Text
Peer Reviewed
See detailEffect of raloxifene and alendronate on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis
Johnell, O; Lu, Y; Seeman, E et al

in Osteoporosis International (2000), 11(S2), 184

Detailed reference viewed: 9 (3 ULiège)
Full Text
Peer Reviewed
See detailRapid and sustained effects of risedronate in reducting hip fracture risk in elderly women with osteoporis
Seeman, E; McClung, M; Zippel, H et al

in Journal of Bone and Mineral Research (2000), 15(S1), 149

Detailed reference viewed: 7 (1 ULiège)